Big gain for MacroGenics after breast cancer readout

MacroGenics Inc. (NASDAQ:MGNX) shares leapt Wednesday after the company said margetuximab led to a survival benefit vs. Herceptin trastuzumab in the Phase III SOPHIA trial to treat HER2-positive metastatic breast cancer. MacroGenics is planning a

Read the full 350 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE